New drug aims to halt lung decline in scarred lungs
Disease control
Ongoing
This trial tests an investigational drug called CAL101 in 150 adults with idiopathic pulmonary fibrosis, a disease that scars the lungs and makes breathing harder. Participants receive monthly IV infusions of CAL101 or a placebo for 6 months. The goal is to see if CAL101 can prev…
Phase: PHASE2 • Sponsor: Calluna Pharma AS • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC